This article is provided for educational and informational purposes only. All compounds discussed are supplied strictly for laboratory and research use. Vitro Labs products are not for human or animal consumption.
CJC-1295 and Tesamorelin are cousins. Both are synthetic compounds built on the same biological blueprint. the first 29 amino acids of human growth hormone-releasing hormone (GHRH), the natural messenger your hypothalamus uses to tell the pituitary gland to release growth hormone. Researchers call that 29-amino-acid fragment GRF(1-29), and it turns out to be the smallest piece of GHRH that still carries the full signaling activity of the parent hormone.
So if they share the same backbone, why do researchers study them as separate compounds? The answer is in the modifications. Each compound tweaks the GRF(1-29) sequence in a different way to solve a different problem. and those tweaks produce dramatically different half-lives, dramatically different research applications, and dramatically different handling considerations in the laboratory.
This guide walks through both compounds in plain English. Mechanism. Structure. Half-life. Key preclinical research. Where the literature on the two converges, and where it splits. For laboratory research use only.
Before getting into the mechanism details, here is the high-level side-by-side. Every number below is grounded in the preclinical and pharmacokinetic literature referenced at the bottom of this article.
| Feature | CJC-1295 (with DAC) | Tesamorelin |
|---|---|---|
| Structural class | GRF(1-29) analog + DAC linker | GRF(1-44) analog with N-terminal modification |
| Key modification | Maleimidopropionic acid linker binds albumin | Trans-3-hexenoyl group at N-terminus |
| Half-life (reported) | ~6-10 days | ~26-38 minutes |
| Receptor target | GHRH-R (pituitary somatotrophs) | GHRH-R (pituitary somatotrophs) |
| GH release pattern | Sustained, low-amplitude elevation | Pulsatile, closer to physiological rhythm |
| Regulatory context | Research compound, not FDA-approved | FDA-approved drug exists; research-grade compound supply is for laboratory research use only |
CJC-1295 is a synthetic compound based on GRF(1-29). the first 29 amino acids of human GHRH. Researchers at ConjuChem developed it in the early 2000s as part of a broader effort to solve a basic biochemistry problem: native GHRH gets chewed up too fast. The enzyme dipeptidyl peptidase-IV (DPP-IV) cleaves the compound within minutes of entering circulation, which means any therapeutic use of native GHRH would require nearly continuous administration.
The CJC-1295 solution was structural. The compound carries four amino acid substitutions at positions 2, 8, 15, and 27 that make it resistant to enzymatic degradation, plus a chemical handle on the C-terminus designed to bind albumin. That handle is the DAC linker, and it is the most important modification on the molecule.
Serum albumin is the most abundant protein in human blood. When CJC-1295’s DAC linker enters circulation, it forms a covalent bond with cysteine-34 on albumin within hours. Once attached, the compound-albumin complex is too large to be filtered out by the kidneys and is shielded from proteolytic enzymes. The result is a dramatic half-life extension. from minutes to days.
Teichman and colleagues at ConjuChem published the original pharmacokinetic characterization in 2006 in The Journal of Clinical Endocrinology & Metabolism. They reported half-life values in the 6-10 day range across their dose-response cohort, and they observed sustained elevations in growth hormone and insulin-like growth factor-1 (IGF-1) measurements for up to 28 days after a single administration (Teichman et al., 2006, PMID: 16940447).
The literature also describes a related compound. CJC-1295 without DAC, sometimes called Modified GRF(1-29) or MOD GRF(1-29). It carries the same four stabilizing amino acid substitutions but lacks the albumin-binding linker. Without DAC, the compound is resistant to DPP-IV degradation but it isn’t anchored to albumin, so it clears the bloodstream in roughly 30 minutes rather than 6-10 days.
That distinction matters for research design. Without-DAC variants produce a short, sharp release of growth hormone that more closely resembles the body’s natural pulsatile GHRH signaling. Studies that want to model physiological GH rhythm tend to use the no-DAC form. Studies that want to maintain sustained GH and IGF-1 elevations over days use the DAC form. They are biochemically distinct research tools, even though they share the same parent sequence.
The four amino acid substitutions on the GRF(1-29) scaffold are: D-alanine at position 2 (protects against DPP-IV cleavage), glutamine at position 8 (resistance to chymotrypsin), alanine at position 15 (additional protease resistance), and leucine at position 27 (oxidation resistance). These substitutions are shared between the DAC and no-DAC variants and are what makes both compounds stable enough to study in the first place.
Tesamorelin is also a GRF analog, but it took a different structural path. Developed by Theratechnologies in the 2000s, it is based on the longer GRF(1-44) sequence (the full bioactive GHRH compound rather than just the 1-29 fragment). The key modification is at the N-terminus: a trans-3-hexenoyl group attached to the tyrosine residue at position 1.
That single chemical modification accomplishes what CJC-1295’s amino acid substitutions accomplish. protection against DPP-IV. But it does so without binding albumin, which means Tesamorelin’s half-life extension is much more modest. Ferdinandi and colleagues reported pharmacokinetic values in the 26-38 minute range in their preclinical characterization studies (Ferdinandi et al., 2007, PMID: 17381366).
The full molecule is a 44-amino-acid compound with the trans-3-hexenoyl group covalently linked to the N-terminal tyrosine. That hexenoyl group is a small fatty acid chain. six carbons with a double bond. and its function is steric. It blocks DPP-IV from accessing the cleavage site without interfering with the receptor-binding region of the compound.
Compared to CJC-1295, the modification is biochemically simpler. There’s no albumin binding, no covalent attachment to a serum protein, no extended residence time. Tesamorelin behaves more like a stabilized version of native GHRH than like a depot-style compound.
Tesamorelin has an unusual position in the GHRH analog landscape because a Tesamorelin-based pharmaceutical product received FDA approval in 2010. That approval was for a specific clinical indication unrelated to general research-grade compound investigation, and the approved drug is distributed through pharmaceutical channels under a different commercial framework.
For preclinical researchers, the regulatory background is mostly relevant for context: it means Tesamorelin has been more thoroughly pharmacokinetically characterized than most research-grade compounds, with published phase I, phase II, and phase III data in the peer-reviewed literature. That published characterization is a useful baseline for designing in vitro and preclinical studies, even though the research-grade compound form is supplied for laboratory use only.
At the receptor level, CJC-1295 and Tesamorelin do the same thing. Both bind the growth hormone-releasing hormone receptor (GHRH-R) on the surface of pituitary somatotroph cells. That receptor is a G-protein-coupled receptor. the same receptor family as most hormone receptors. and binding triggers a well-characterized intracellular signaling cascade.
The GHRH-R is selective for GHRH and its close analogs. It does not bind growth hormone secretagogue receptor (GHS-R) ligands like ghrelin, ipamorelin, or hexarelin. those engage a separate pathway. The selectivity matters for research design: combining a GHRH analog with a GHS-R agonist produces synergistic GH release because the two receptors engage independent intracellular cascades that converge on growth hormone secretion.
Mayo and colleagues’ work on GHRH-R structure and function (Mayo, 1992, PMID: 1331777) characterized the receptor’s binding pocket and demonstrated that both GHRH(1-29) and GHRH(1-44) bind with comparable affinity. That is the structural basis for why CJC-1295 (based on 1-29) and Tesamorelin (based on 1-44) produce similar receptor-level effects despite their different sequence lengths.
Once GHRH-R is engaged, the downstream signaling is well-mapped. The receptor couples to the Gs alpha subunit of its associated G protein. Gs alpha activates adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). Rising cAMP activates protein kinase A (PKA), which phosphorylates a series of downstream targets. most importantly, the transcription factor CREB (cAMP response element-binding protein).
Bilezikjian and Vale characterized the cAMP cascade in pituitary cells in detail (Bilezikjian and Vale, 1983, PMID: 6307673), demonstrating that GHRH-induced cAMP elevation is necessary and sufficient for growth hormone release in somatotrophs. The cascade is conserved across both CJC-1295 and Tesamorelin engagement. the molecular response inside the cell is the same regardless of which analog is bound to the receptor.
Here is where the two compounds diverge dramatically. The body’s natural GHRH signaling is pulsatile. short bursts every few hours, with low baseline between bursts. Tesamorelin’s 26-38 minute half-life preserves something close to that natural rhythm, especially when administered in a research model designed to mimic physiological dosing.
CJC-1295 with DAC produces a fundamentally different pattern: sustained, low-amplitude GHRH-R engagement over days. That sustained engagement can blunt the natural pulsatile rhythm because the receptor is occupied continuously rather than intermittently. Whether that pattern is desirable depends on the research question. Studies investigating chronic GH/IGF-1 axis modulation tend to use DAC variants. Studies investigating pulsatile GH dynamics or trying to preserve natural rhythm use Tesamorelin or no-DAC CJC-1295.
“Sustained GHRH receptor activation produces qualitatively different growth hormone secretion patterns compared to pulsatile activation, with implications for downstream IGF-1 signaling.”
, Synthesizing Teichman et al. (2006), PMID: 16940447, and Ferdinandi et al. (2007), PMID: 17381366
The published research bases for the two compounds are similar in shape but differ in volume. Tesamorelin has more clinical trial data because of its pharmaceutical development pathway; CJC-1295 has more pharmacokinetic and preclinical biomarker data from its ConjuChem development program.
The Teichman et al. (2006) pharmacokinetic study remains the foundational reference for CJC-1295 with DAC. The study characterized half-life, GH and IGF-1 response curves, and dose-response relationships in healthy adult research subjects. The most striking finding was the duration of biomarker response. IGF-1 elevations were measurable for up to 28 days after a single administration in the highest dose cohort (Teichman et al., 2006, PMID: 16940447).
Subsequent preclinical work has examined CJC-1295’s effect on GH pulse amplitude versus baseline, with reports of 3- to 5-fold increases in baseline GH levels under sustained dosing while pulse amplitude is somewhat blunted (Ionescu and Frohman, 2006, PMID: 16940458).
Tesamorelin’s preclinical and clinical research base is larger by volume. Ferdinandi et al. (2007) characterized the pharmacokinetic profile in detail (PMID: 17381366), establishing the 26-38 minute half-life range and demonstrating dose-proportional GH responses across a wide dose range.
Additional preclinical work has examined Tesamorelin’s effects on IGF-1 axis modulation and the durability of receptor sensitivity over repeated administration. Falutz and colleagues’ phase II and phase III data, while focused on a specific clinical context, provided some of the most rigorous pharmacokinetic and pharmacodynamic characterization of any GHRH analog in the published literature (Falutz et al., 2007, PMID: 17605818).
Both compounds have been studied for their effects on the GH/IGF-1 axis, and the published findings converge on several points. First, both reliably increase circulating GH and IGF-1 in research models in a dose-dependent manner. Second, both preserve the physiological feedback loop. meaning somatostatin (the inhibitory counterpart to GHRH) can still suppress GH release, which suggests the GHRH-R remains responsive rather than constitutively activated.
Where the literature diverges is in long-term receptor dynamics. Studies of CJC-1295 with DAC raise questions about receptor desensitization under sustained exposure. questions that don’t arise as clearly for Tesamorelin because its short half-life means receptor occupancy is intermittent. Direct head-to-head comparison studies between the two compounds are limited; most of what we know comes from parallel literature streams rather than side-by-side investigations.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. CJC-1295 and Tesamorelin are research compounds. The research-grade compound form of Tesamorelin is not the FDA-approved pharmaceutical product. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
The structural differences between CJC-1295 and Tesamorelin translate into different laboratory handling considerations. Both arrive as lyophilized powder, both require reconstitution with a sterile diluent, and both are sensitive to degradation. but the specifics differ.
Both compounds are supplied in lyophilized form, which is essentially a freeze-drying process that removes water under vacuum and leaves a stable powder. Lyophilization is the standard format for research-grade compounds because dry compounds are dramatically more stable than aqueous solutions. most amide bonds are vulnerable to hydrolysis when water is present.
For both compounds, identity and purity verification typically involves HPLC and mass spectrometry. Purity targets of ≥98% are common in research-grade material, and a batch-specific Certificate of Analysis from an independent laboratory is the standard documentation researchers verify before adding new material to laboratory inventory. Vitro Labs supplies both compounds with batch-specific COAs from Freedom Diagnostics, an ISO-certified analytical lab.
Reconstitution typically uses bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative). The choice of diluent affects post-reconstitution stability. bacteriostatic water extends usable shelf life relative to plain sterile water because the benzyl alcohol suppresses microbial growth that would otherwise accelerate compound degradation.
Lyophilized CJC-1295 and Tesamorelin are both stable for extended periods at -20°C in a sealed vial protected from light. After reconstitution, both compounds become substantially less stable. Aqueous compound solutions are vulnerable to several degradation pathways: hydrolysis of amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and cysteine residues, and physical aggregation.
Standard laboratory protocols for both compounds are similar: reconstituted material stored at 2-8°C is typically considered usable for 2-4 weeks; longer-term storage requires -20°C with aliquoting to avoid freeze-thaw cycles. For exact stability windows, researchers should refer to the batch-specific COA and published compound stability literature.
The decision between CJC-1295 and Tesamorelin for a research protocol comes down to the experimental question, not to compound superiority. Neither is “better” in any absolute sense. they are different research tools.
Researchers investigating sustained GHRH-R engagement, chronic GH/IGF-1 axis modulation, or long-duration pharmacokinetic profiles tend to use CJC-1295 with DAC because the long half-life allows for less frequent administration in research designs that span days or weeks. Researchers investigating pulsatile GH dynamics, physiological signaling rhythms, or shorter-duration responses tend to use Tesamorelin or no-DAC CJC-1295 because the shorter half-life preserves something closer to natural GHRH kinetics.
Many research designs also combine a GHRH analog with a growth hormone secretagogue receptor (GHS-R) agonist such as ipamorelin to study receptor synergy. Vitro Labs supplies CJC-1295 + Ipamorelin as a blend for laboratory research investigation of that synergy. For Tesamorelin-based protocols, the standalone Tesamorelin 5mg vial is the standard research format.
⚠️ Research Disclaimer: This article is for educational and informational purposes only. All compounds discussed are research chemicals for laboratory research use only and are not for human consumption. Tesamorelin as supplied for laboratory research is not the FDA-approved pharmaceutical product.
The main difference is the structural modification used to extend half-life. CJC-1295 (with DAC) uses a maleimidopropionic acid linker that binds serum albumin, pushing the half-life to 6-10 days (Teichman et al., 2006, PMID: 16940447). Tesamorelin uses a trans-3-hexenoyl group at the N-terminus that provides protease resistance without albumin binding, producing a much shorter half-life of roughly 26-38 minutes (Ferdinandi et al., 2007, PMID: 17381366). Both engage the same GHRH receptor and the same downstream cAMP/PKA cascade. For laboratory research use only.
Yes. Both compounds are GHRH analogs and both bind the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotroph cells. The receptor is a G-protein-coupled receptor, and binding triggers a cAMP/PKA signaling cascade that drives growth hormone gene transcription and secretion. Mayo’s structural characterization of GHRH-R (1992, PMID: 1331777) demonstrated that both GHRH(1-29) and GHRH(1-44). the parent sequences of CJC-1295 and Tesamorelin respectively. bind with comparable affinity.
Half-life is the headline difference. CJC-1295 with DAC carries a maleimidopropionic acid linker that covalently binds serum albumin, extending the half-life to 6-10 days. CJC-1295 without DAC (sometimes called Modified GRF(1-29)) has the same four stabilizing amino acid substitutions but lacks the albumin-binding linker; its half-life is approximately 30 minutes. The two are biochemically distinct research compounds despite sharing the same parent sequence. Researchers investigating sustained GHRH-R engagement use the DAC form; researchers investigating pulsatile signaling tend to use the no-DAC form or Tesamorelin.
A pharmaceutical product containing the Tesamorelin molecule received FDA approval in 2010 for a specific clinical indication and is distributed through pharmaceutical channels under a separate commercial framework. The research-grade compound form of Tesamorelin supplied by research chemical vendors is a different product. provided strictly for laboratory and in vitro research applications, not for human consumption, and not intended to substitute for any prescription medication. The regulatory existence of an approved drug does not change the research-use-only status of the compound as supplied for laboratory investigation.
Both are supplied as lyophilized (freeze-dried) powder in sealed vials and stored at -20°C protected from light. Researchers reconstitute the powder with bacteriostatic water before laboratory use. After reconstitution, both compounds become substantially less stable due to hydrolysis, deamidation, oxidation, and aggregation pathways. Best practice is to aliquot reconstituted material into single-use volumes to avoid freeze-thaw cycles. Identity and purity are verified per batch via HPLC and mass spectrometry, with batch-specific Certificates of Analysis from an independent analytical laboratory documenting the verification.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. CJC-1295 and Tesamorelin are research compounds. The research-grade compound form of Tesamorelin is not the FDA-approved pharmaceutical product. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
